Underwriters Exercise Option on Rosetta Public Offering; Total Gross Proceeds Rise to $31.6M | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the underwriter for its recent public offering has exercised an overallotment option to purchase 825,000 additional shares of the company's common stock, bringing the total gross proceeds from the offering to $31.6 million.

Aegis Capital was the sole book-running manager on the offering. Rosetta completed the public offering of 5.5 million shares at $5 per share earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.